Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.30 |
| ▸ | LOX | P28300 | 1/20 | 0.30 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497902 | 0.90 | MTNR1A (0.37) | MTNR1AMTNR1BNNMTMEN1KMT2A | |
| SCHEMBL2543745 | 0.84 | MTNR1A (0.33) | MTNR1AMTNR1BNNMTMEN1KMT2A | |
| SCHEMBL31573501 | 0.83 | NNMT (0.38) | MTNR1AMTNR1BNNMTMEN1KMT2A | |
| SCHEMBL17310189 | 0.83 | NNMT (0.38) | MTNR1AMTNR1BNNMTMEN1KMT2A | |
| SCHEMBL1922545 | 0.79 | NNMT (0.45) | MTNR1AMTNR1BTNKS2NNMTGCK | |
| SCHEMBL18083204 | 0.78 | NNMT (0.39) | MTNR1AMTNR1BNNMTMEN1KMT2A | |
| SCHEMBL30486638 | 0.78 | NNMT (0.35) | MTNR1AMTNR1BNNMTMEN1KMT2A | |
| SCHEMBL9013521 | 0.78 | NNMT (0.35) | MTNR1AMTNR1BNNMTMEN1KMT2A | |
| SCHEMBL21591699 | 0.75 | MTNR1B (0.51) | MTNR1AMTNR1BNNMTMEN1KMT2A | |
| SCHEMBL21591621 | 0.74 | ALDH1A1 (0.34) | MTNR1AMTNR1BNNMTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190811-B1 | RENIN INHIBITORS | MERCK CANADA INC (CA) | 2013-08-07 | — | — | EP | disclosed |
| US-8334308-B2 | Renin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110263658-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-10-27 | — | — | US | disclosed |
| EP-2190811-A1 | RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009023964-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263658-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | MTNR1A 940/4885MTNR1B 349/4885TNKS2 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.